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Abstract
Background: About 30 % of the patients initiated on antiretroviral therapy in Zambia default treatment. Some of
these patients later restart treatment; however, the characteristics of these patients have not been well described
and documented. The aim of this study was to describe and document the socio-demographic and clinical
characteristics of patients who default and restart antiretroviral therapy, and to determine the socio-demographic
characteristics associated with CD4 count response at 6 and 24 months of restarting antiretroviral therapy.
Methods: A longitudinal retrospective analysis was performed on data from 535 adult patients restarting
antiretroviral therapy in 2009 and 2010 at five antiretroviral therapy centres in Copperbelt and Central provinces of
Zambia. To determine the association between the socio-demographic characteristics and CD4 cell count, quantile
regression models were used.
Results: Older age above 45 years was associated with a significantly lower CD4 cell response by 38.1 cells/mm3
(95 % Confidence interval [CI]: −109.4 to −0.2) compared to the younger age (15–29 years). Patients in formal
employment (Adjusted Coefficient [AC] 29.5, 95 % CI: 22.8 to 81.1) and self-employment (AC 48.1, 95 % CI: 18.6 to
77.4) gained significantly higher CD4 cells than those unemployed. In addition, baseline CD4 count, type of
treatment, WHO staging, total duration on treatment and duration lost to follow-up were found to be strong
predictors of CD4 cell count at 6 and 24 months after restarting antiretroviral therapy treatment.
Conclusion: Age and occupation were the only socio-demographic characteristics predicting CD4 count in the
patients at 6 months after restarting antiretroviral therapy after adjusting for other confounding clinical variables.
Keywords: CD4 cell count, Antiretroviral therapy, Restart, Defaulting, Lost to follow-up, Zambia
Background
Antiretroviral therapy (ART) is an essential part of the
fight against the human immunodeficiency virus (HIV)
and acquired immunodeficiency syndrome (AIDS), sus-
tains human lives for people living with HIV (PLHIV)
and prevents HIV/AIDS morbidity and mortality [1].
ART though expensive, in the long run saves money
and promotes development [2]. While the benefits
and successes of ART have been widely acknowledged
worldwide [1, 3–6], about 30 % of the patients are lost to
follow-up (LTFU) from treatment in programmes in most
developing countries [7–10]. However, some of the pa-
tients who interrupt ART later restart the treatment. This
interruption of ART prevents patients from reaping the
full benefits of the treatment [2].
LTFU was defined in the 2010 Zambia ART guidelines
as missing a scheduled pharmacy pick-up for more than
60 days [11]. Patients who came back to ART after LTFU
were considered to have restarted ART. Therefore, treat-
ment resumption in this study was defined as restarting
ART after the patient was declared LTFU at the health
facility. Defaulting results in treatment interruption,
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which has negative effects on the CD4 cell response of the
patient. Patients who default and restart ART run a higher
risk of illness and death because of AIDS-related condi-
tions [3, 4, 10, 12–18]. Defaulting may, therefore, result in
patients restarting ART at an increased viral rebound,
acute retroviral syndrome due to immune decomposition
and an increased risk of HIV transmission [19].
It has been suggested that patients who restart ART
normally resume treatment at a CD4 count level lower
to their CD4 count prior to ART defaulting but similar
to the CD4 count at first ART initiation [17]. This un-
derscores the potentially negative impact of treatment
defaulting that might lead to a reversal of the immuno-
logical recovery made while on the initial treatment [20].
Defaulting ART has also been associated with age, gen-
der, residency and self-rate health. In some studies
Younger age or female gender or patients with CD4
counts >350 cells/mm3 were found to be more likely to
default. Other studies established positive significant as-
sociations between restarting ART with older age or fe-
male gender or urban residency or shorter time since
defaulting [18, 21–23]. Despite knowing the factors asso-
ciated with defaulting and restarting ART, the social and
clinical characteristics of such patients who default and
restart have not been well described and documented in
Zambia where the attrition rate of patients is still high
[8]. Therefore this study aimed at describing and docu-
menting the socio-demographic and clinical characteris-
tics of patients who defaulted and restarted ART from
January, 2009 to December, 2010 in Zambia; and also to
determine the socio-demographic and clinical character-
istics associated with CD4 count response at 6 and
24 months after restarting ART.
Methods
Study design and sampling
A retrospective longitudinal study design was used.
Patients who restarted ART between January 2009 and
December 2010 were sampled from five Ministry of
Health-Owned ART health facilities that were supported
by the FHI 360-led Zambia Prevention, Care and Treat-
ment project. These ART facilities were purposively se-
lected from the Central and Copperbelt provinces because
of the high restarting rates recorded during the selected
period. The health facilities selected in Central Province
were Liteta Hospital, Kabwe General Hospital and
Mwachisompola Demo Zone and in Copperbelt Province
Kitwe Central Hospital and Chipokota Mayamba Health
Centre. At these five selected ART facilities, all adult pa-
tients, male and female ≥16 years who were restarted on
ART in the period January 2009 to December 2010 were
included in the study. Paediatric patients (below 15 years),
pregnant women and patients transferred in and out
during the study period were excluded.
Study population
Women and men enrolled in the ART care and reported
to have defaulted and restarted ART services from January
2009 to December 2010 were selected for this study. All
the five ART facility chosen were high volume facilities
and served geographically and socially discreet catchment
populations and received referrals from smaller health fa-
cilities within their catchment areas. ART health care ser-
vices were accessible and ran throughout the week as part
of the primary health services provided by the hospitals.
The population was selected because they had access to a
comprehensive package of ART care, which included HIV
counselling and testing and provision of ART.
Data collection
A data extraction sheet was used to excerpt the patient
data from the FHI 360 supported database (Smartcare)
at the ART facilities. Smartcare is an electronic database
system where all the records collected from the patients
at the ART clinic were entered and stored. For clinic re-
views five Smartcare forms were used and these were:
the Patient Locator form used to take the patient details
about residency and next of kin; the Initial History and
Patient form where the initial detailed history of the pa-
tient was recorded before they were initiated on ART;
Eligibility/Initiation form which was used to asses eligi-
bility for ART; the Clinical Follow-up form used for sub-
sequent reviews once the patient was initiated on ART
and the Patient Status which was filed in when the status
(such as defaulting, restarting, transfer and or death) of
the patient changed.
The extraction of data was done by trained FHI 360 data
collectors, stationed at the ART facilities selected in this
study. The data collection process included the review of
the laboratory forms in the patient file and five Smartcare
forms which were either electronic or paper based.
All the patients listed in Smartcare, who had defaulted
and restarted ART were eligible for the study. A
complete list of 535 patients who were restarted on ART
during the period of interest was generated by running a
Data Quality Report (DQR) in Smartcare which gave a
list of names and patient file numbers of all those who
were recorded as restarted after having defaulted ART.
The file numbers from the generated list were then used
to consolidate both the electronic and paper based pa-
tient files. After merging both the Smartcare and paper-
bases patient files, the information required was then
collected using the data collection form. This data for
each patient was retrospectively collected at 6 months
and 24 months after restarting ART.
Ethical issues
The ERES Coverage ethics committee approved this
study. Permission to conduct the study was granted
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by FHI 360 Zambia, Ministry of Health (MoH) and
the District authorities in charge of the ART facilities.
Confidentiality was upheld throughout the research
period.
Statistical analysis
Data from the data collection form was entered in an ac-
cess database and later exported to SPSS version 20 and
STATA version 12 for analysis. Quantile regression was
used to determine the association between CD4 count at
6 and 24 months (dependent variables) and the inde-
pendent variables. Quantile regression analysis was
chosen because the outcome variable (CD4 count) was
discrete and not normally distributed. The median was
used to assess associations of the dependent variable
with the independent variables adjusted for baseline
CD4 count at the time of restarting ART. Clustering
effect was taken into consideration by adjusting for the
different ART facilities were data was collected. Statistical
comparisons were made within the groups [24].
Results
Characteristics of study participants
The study reviewed 535 records of patients who
defaulted and restarted ART at the five ART facilities. Of
the 535 patients, 71 (13.3 %) were from Chipokota
Mayamba, 89 (16.6 %) from Kabwe General Hospital,
119 (22.2 %) from Kitwe Central Hospital, 31 (5.8 %)
from Mwachisompola Demo Zone and 225 (42.1 %)
Liteta Hospital. The socio-demographic characteristics
of the 535 patients restarted on ART are shown in
Tables 1 and 2. More than half of the participants 56.6 %
(303) were female while 43.4 % (232) were male. The
median age of the patients was 37 years (Interquartile
range [IQR] 31 to 43 years) with the minimum age of 17
and the maximum age of 65 years. More than forty per-
cent (43.0 %, n = 230) of these patients were falling in
the age group 35–44 years. In terms of education,
19.3 % (103) of the patients had no education, 61.1 %
(327) had attained some education (ranging from pri-
mary to secondary education) while the remaining
16.4 % (88) had attained tertiary education (college or
university). In addition, 36.4 % (n = 195) of the patients
were self-employed, 35.5 % (190) were unemployed and
21.3 % (n = 114) were in formal employment. Tables 1
and 2 also shows that 84.3 % of the patients were in
WHO stage 3 (n = 245; 46.2 %) and WHO stage 4
(n = 202; 38.1 %) at the time of restarting ART.
Figure 1 shows boxplots of interquartile range of CD4
count at restart of ART, 6 and 24 months after restarting
ART. The median CD4 count at restart of ART was 213
(IQR, 132 to 306), 323 (IQR, 221 to 420) at 6 months
and 476 (IQR, 355 to 612) at 24 months after restarting
of ART.
Quantile regression at 6 months
Quantile regression analysis at 6 months after restarting
ART showed that age, occupation, type of treatment,
WHO staging, CD4 count, total duration on treatment
and duration of LTFU were significantly associated with
CD4 count at both bivariate and multivariable analysis
(Table 3). Age group and occupation were the only
socio-demographic characteristics that predicted CD4
count cell response at 6 months. Patients in the age
group ≥45 years had a significantly lower CD4 count at
6 months by 7.9 cells/mm3 (95 % CI: −48.1 to −2.7)
compared to patients in the age group of 15 to 34 years.
In terms of occupation, patients had a significantly
higher CD4 count at 6 months if they were in formal
employment (Adjusted Coefficient [AC] 29.5, 95 % CI:
Table 1 Socio-demographic and Clinical Characteristics for 535
Patients at ART Restart
Frequency Percentage
Sex Male 232 43.4
Female 303 56.6









Level of Education None 103 19.3
Highest Grade (1–12) 327 61.1
College/university 88 16.4
Missing 17 3.2
Occupation Unemployed 190 35.5
Self-employment 195 36.4
Formal Employment 114 21.3
Other 14 2.6
Missing 22 4.1
WHO staging Stage 4 202 38.1
Stage 3 245 46.2
Stage 2 69 13.0
Stage 1 14 2.6
Table 2 Socio-demographic and Clinical Characteristics for 535
Patients at ART Restart
Median (IQR) Minimum maximum
Weight (Kg) 55 (48–61) 20 100
CD4 count 213 (132–306) 1 1556
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22.8 to 81.1) compared to patients who were unemployed;
and patients in self-employment showed a significant in-
crease in CD4 cell count by 26.4 cells/mm3 (95 % CI: 12.2
to 64.9) compared to patients who were unemployed.
The results show that the patients had a significantly
lower CD4 count at 6 months if they were receiving sec-
ond line ART compared to those receiving first line
ART; the CD4 was lower by 65.2 cells/mm3 (95 % CI:
−127.8 to −2.5). The patients also showed a significantly
lower CD4 count at 6 months if they were in WHO
stage 4 (AC 147.8, 95 % CI: −267.5 to −31.8); in WHO
stage 3 (AC 116.2, 95 % CI: −230.5 to −50.9) and in
WHO stage 2 (AC18.5, 95 % CI: −59.3 to −9.2) com-
pared to those in WHO stage 1 (Table 3). Furthermore,
one-month increase in total duration on treatment sig-
nificantly increased the CD4 count at 6 months by 0.4
cells/mm3 (95 % CI: 0.1 to 0.8).
Duration on treatment before LTFU and duration of
LTFU were only significantly associated with CD4 count
at 6 months at multivariable analysis. One-month increase
in duration LTFU significantly decreased the CD4 count
at 6 months by 1.3 cells/mm3 (95 % CI: −1.9 to −0.9) while
duration before LTFU significantly increased the CD4
count by 1.4 cells/mm3 (95 % CI: 0.5 to 3.5). At bivariate
analysis, one unit increase in CD4 count at ART restart
increased the CD4 count at 6 months by 0.2 cells/mm3,
with a range of 0.1 cells/mm3 to 0.3 cells/mm3.
Quantile regression at 24 months
Using CD4 count at 24 months as the dependent, three
independent variables were statistically significant and
these were age group, total duration and CD4 count
at 6 months. The age group of ≥45 years showed a
significantly lower CD4 count by 38.1 cells/mm3
(95 % CI: −109.4 to −0.2) compared to the age group
of 15–34 years. One unit increase in CD4 count at
6 months increased the CD4 count at 24 months by
0.9 cells/mm3, with a range of 0.5 cells/mm3 to 1.1
cells/mm3. One month increase in total duration on
treatment increased the CD4 count at 24 months by
0.2 cells/mm3 (95 % CI: 0.1 to 0.4).
At bivariate analysis, CD4 count at restart of ART,
WHO staging and facility were significantly associated
with CD4 count at 24. One unit increase in CD4 count
at restart of ART increased the CD4 count at 24 months
by 0.4 cells/mm3 (95 % CI: 0.3 to 0.5). The patients con-
sistently showed a significantly lower CD4 count if in
WHO stage 4 (UC −97.8, 95 % CI: −183.2 to −7.9), in
WHO stage 3 (UC −67.4, 95 % CI: −113.5 to −2.3) and
in WHO stage 2 (UC −45.1, 95 % CI: −145.6 to −5.7)
compared to those in WHO stage 1. Patients from
Kabwe general hospital showed a significant increase in
CD4 count at 24 months by 15.7 cells/mm3 (95 % CI:
5.6 to 157.5) than the other facilities.
Discussion
The study demonstrates that different individuals will
exhibit different responses in CD4 cell count after
restarting ART. Age, occupation, type of treatment, total
duration on treatment, duration of LTFU, duration on
treatment before LTFU and previous CD4 count were
associated with CD4 cell count at 6 months after restart-
ing ART. At 24 months after restarting ART, three (3)
variables were significantly associated with CD4 count
and these were Age, CD4 count at 6 months and total
duration on treatment.
Fig. 1 Boxplots of Interquartile range of CD4 count at restarting ART, 6 and 24 months after restaring ART
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In this study, most of the patients who restarted ART
were ≥35 years. The patients in the age group of ≥45 years
showed a significant lower CD4 count at 24 months as
compared to the age group 15–34 years. Younger age may
be associated with better CD4 cell count recovery while
older age maybe associated with a weaker immunity sys-
tem, which makes the immunological recovery slower.
The older patients may also be more likely to develop
more severe opportunistic infections associated with old
age than the younger age group even after they resume
ART. This result is consistent with the study done on
adults in South Africa, which found that resumption of
ART was more likely in patients ≥30 years old than
those who are younger [18]. Furthermore, in a cohort
study conducted in a hospital setting in Brazil, patients
over 40 years of age were reported to present lower in-
crease in CD4 cell count over time compared to the
younger age group [25]. This result may have important
Table 3 Quantile logistic regression model on CD4 count of the patients at 6 and 24 months after restarting ART
Independent Variable Median CD4
At 6 Months At 24 Months
UCa (95 % C.I) ACb (95 % C.I) UCa (95 % C.I) ACb (95 % C.I)
Sex Male 1 1 1 1
Female 70.3 (48.2;91.7) 19.8 (−10.9;50.4) 37.7 (−25.1;99.2) 19.5 (−65.1;104.2)
Age Group 15–34 1 1 1 1
35–44 18.5 (2.3;48.8) 20.3 (−1.6;49.7) 16.8 (−56.6;88.5) −24.2 (−119.4;71.6)
45+ −10.7 (−55.3;−5.3) −7.9 (−48.1;−2.7) 18.2 (−63.7;99.8) −38.1 (−109.4; −0.2)
Occupation Unemployed 1 1 1 1
Self-employment 48.9 (18.6;77.4) 26.4 (12.2;64.9) 18.9 (−46.3;82.5) −5.3 (−112.3;101.6)
Formal employment 18.1 (−16.3;52.2) 29.5 (22.8;81.1) 24.0 (−51.8;99.5) 4.7 (−130.6;139.9)
Other 120.2 (38.8;84.9) 104.0 (7.4;200.5) 41.9 (−101.8;183.2) 3.1 (−230.6;236.8)
Education None 1 1 1 1
Highest Grade (1–12) 16.0 (−28.6;60.6) 26.4 (−16.3;69.4) 33.1 (−39.9;105.1) −8.3 (−125.1;108.5)
College/University −5.6 (−59.7;49.7) −0.2 (−64.8;64.4) 15.6 (−77.3; 107.8) 21.3 (149.6;192.2)
Marital status Unmarried 1 1 1 1
Married 10.7 (−34.4;54.4) −9.3 (−52.9;34.4) −20.7 (−108.9;68.4) 39.7 (−96.5;175.9)
Divorced 13.6 (−46.1;72.1) −8.0 (−65.7;49.6) 44.3 (−66.5;154.0) 20.1 (−144.1;184.3)
Widowed −14.0 (−75.5;47.5) −5.1 (−66.1;55.8) −2.9 (−116.4;112.0) 35.7 (−136.4;207.7)
Type of treatment 1st line 1 1 1 1
2nd line −80.2 (−140.4;−19.6) −65.2 (−127.8;−2.5) −78.8 (−186.8;30.6) 10.8 (−156.1;177.8)
WHO Staging Stage 1 1 1 1 1
Stage 2 −27.4 (−64.3; −10.3) −18.5 (−59.3;−9.2) −45.1 (-145.6;−5.7) −4.7 (−85.7; 14.1)
Stage 3 −106.2 (−252.5;−68.5) −116.2 (−230.5;−50.9) −67.4 (−113.5;−2.3) −30.0 (−148; 6.1)
Stage 4 −132.1 (−281.3;−77.9) −147.8 (−267.5;−31.8) −97.8 (−183.2;−7.9) 3.4 (−145.6;152.4)
Facility Chipokota Mayamba Clinic 1 1 1 1
Kabwe General Hospital 21.7 (−25.0;67.3) 11.1 (−41.8;32.1) 15.7 (5.6;157.5) −15.4 (−185.6;154.7)
Kitwe Central Hospital −34,6 (−82.9;14.7) −27.3 (−85.7;31.0) −4.5 (−94.4;88.9) −57.9 (−225.3;109.4)
Liteta Hospital 24.5 (−20.3;68.0) 11.2 (−37.4;59.8) 70.3 (−13.8;153.4) 15.6 (−131.2;162.5)
Mwachisompola Demo Zone 48.3 (−30.3;126.2) 24.6 (−62.9;111.9) 121 (−7.2;249.9) 64.1 (−248.1;376.3)
CD4 Count CD4 count at restart 0.2 (−0.1;03) 0.4 (0.3;0.5)
At 6 months 0.9 (0.7; 1.1) 0.9 (0.5;1.1)
Total Duration on treatment 0.4 (0.1;0.8) 1.2 (0.5;3.7) 0.2 (−1.2;1.6) 0.2 (0.1;0.4)
Duration LTFU −0.05 (−0.7;0.8) −1.3 (−1.9;−0.9) −0.1 (−1.9;1.6) 1.9 (−4.2;8.2)
Duration on treatment
before LTFU
0.2 (−1,1;1.5) 1.4 (0.5;3.5) I.6 (−2.0;4.1) 0.5 (−4.6;5.5)
aUnadjusted Coefficient (UC); bAdjusted coefficient (AC), adjusted for sex, age group, occupation, education level, marital status, occupation, type of treatment,
duration and CD4 count
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public health implications in the administration and re-
tention of older patients in ART care.
Patients in formal and self-employment showed a
higher CD4 cell count increase as compared to those
unemployed and this higher CD4 count was attained in
the first year of restarting ART. It is a well-known fact
that paid work is good for health and may improve ac-
cess to health services (including ART care) through
employer-sponsored health programmes [26]. The in-
come status of an individual and the family dynamics
have been reported to influence the health outcome of
the patients on ART. Poor living conditions and failure
to meet the indirect cost of ART were factors preventing
patients from complying with treatment. As a result, pa-
tients with less income have been reported to be 10
times more likely to experience negative life events than
patients with high income [26, 27]. This could be the
reason why patients in formal and self-employment
showed a higher CD4 count increase in this study. In
line with this assumption, approaches that aim at im-
proving ART care services must include interventions
that deliberately focus on ensuring high levels of
adherence and low LTFU. These interventions must
be tailored differently and specifically for employed
and non-employed patients.
In this study, there was no significant association
between education level and CD4 count response at
both 6 and 24 months after restarting ART. This could be
because the definition for highest grade one to
twelve (1–12) in the secondary data used was too
broad ranging from primary (grade one) to secondary
education (grade 12). Patients who had attained grade
one level of education may not be different from those
with no education.
In addition to the socio-demographic characteristics
associated with CD4 count cell response; CD4 count at
restart of ART and WHO stage of the patient were asso-
ciated with CD4 count cell response at 6 and 24 months
after restarting ART. The median CD4 count of the pa-
tients restarted on ART was <350 cells/mm3 and most
of the patients were in WHO stage 4. According to the
Zambian National ART Guidelines for 2009 and 2010,
patients qualified to be initiated on ART if they pre-
sented with CD4 count <350 cells/mm3 and were in
WHO stage three or four. However, patients who had
defaulted ART were restarted regardless of their CD4
cell count [28–30]. This eligibility criteria were recom-
mendations for patients who were initiating ART for the
first time but not patients who were restarting ART.
As the patients continued on treatment more and
more patients moved to WHO stage 1, as a result, over
83.6 % of the patients were in WHO stage 1 and 2 by
the end of 24 months. This was expected in the present
study as it has been a trend in previous studies [27, 31].
However, results in this study show that despite being
on treatment for 24 months, some patients still
remained in WHO stage 4 indicating the negative effect
of interrupting ART. This may be because treatment
interruption in patients may affect the CD4 cell count
response negatively after restarting ART [17]. Treatment
interruption is also associated with increased risk of dis-
ease progression and death [3, 32]. This could explain
why the majority of the patients restarting ART were in
WHO stage 4 and not the asymptomatic WHO stage 1.
The increment in the number of patients in WHO
stage 1 is an indicator that patients who restart ART are
likely to respond well to treatment as suggested by the
study which was done in rural Zambia and in settings
with inadequate HIV treatment available [19, 33]. Simi-
larly, the current study shows that at both 6 and
24 months after restarting ART, the CD4 count of the
patients in WHO stage 2, 3 and 4 increased but was in-
ferior to the increase observed in patients who restarted
ART in WHO stage 1. This may be due to the reason
that baseline CD4 count is one of the most important
determinant of subsequent CD4 cell count trajectories in
both patients that are initiated on ART for the first time
and those that default and restart ART [34]. These
results though obtained from two different groups are
comparable. It can, therefore, be suggested that there
might be no difference in CD4 count responses between
patients who restart and those initiated on ART for
the first time. However, there is need for further re-
search in this area.
Conclusion
The results in this study are crucial to understand the
social and clinical characteristic of patients who default
and restart ART in Zambia. The socio-demographic
characteristics show that patients that restart are more
likely to be aged 35 years and above, married, and must
have gone to either primary or secondary level of educa-
tion. CD4 cell count of the patients who restart ART
was associated with age, occupation, type of treatment,
CD4 at ART restart and CD4 count at 6 months after
restarting ART. These significant associations were
observed as early as 6 months after restarting ART
and seemed to be confounding.
The finding of this study must be considered in light
of the limitations of this study. Firstly, data was collected
retrospectively hence some variables had missing infor-
mation which caused the sample size to vary at each
stage of the analysis. However, the variables and patient
files with significant missing data were excluded during
data analysis. All the main predictors for the dependent
variable were also adjusted for at each stage of analysis
thereby minimizing potential bias in the main results
due to confounding. Furthermore, the reason as to why
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the patients at Kabwe General Hospital recorded a sig-
nificantly higher increase in CD4 count as compared to
other facilities is not known because the data was col-
lected retrospectively. Secondly, adherence to ART after
restarting was based on the records from the pharmacy
pick-up of the medication. Finally, this study was con-
ducted at only 5 ART facilities in the Copperbelt and
Central provinces of Zambia which were purposively
sampled. Therefore, the results can only be generalized
to similar settings but not for the country.
The outcome of the research suggest that, ART as the
essential and vital medicine used to the fight against
HIV/AIDS, sustain human lives and prevent HIV/AIDS
morbidity and mortality can only give the full benefits
when patients stop defaulting and those who restart ad-
here to treatment after restarting.
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